JLJun-Feng Luo

Jun-Feng Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun-Feng Luo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Cong Zhou

    Institute of Seekya Breath Test Technology, Shenzhen, CHINA

    1 shared publication
  • Guo-Liang Zhu

    Institute of Seekya Breath Test Technology, Shenzhen, CHINA

    1 shared publication
  • Hong-Wei Chu

    Guangdong Breath Test Engineering and Technology Research Center, Shenzhen University, Shenzhen, China

    1 shared publication
  • Hou-De Zhang

    Department of Gastroenterology, Nanshan Hospital, Guangdong Medical University, Shenzhen, China

    1 shared publication
  • Hou‐De Zhang

    Institute of Breath Test Research, Shenzhen University, Shenzhen, China

    1 shared publication
  • Jiu-Hong Li

    Department of Nephrology, Nanshan Hospital, Guangdong Medical University, Shenzhen, China

    1 shared publication

Latest Publications

  • Open Access

    Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease

    by Jiu-Hong Li, Jun-Feng Luo, Ying Jiang, Yong-Jian Ma, Yong-Qiang Ji, Guo-Liang Zhu, Cong Zhou, Hong-Wei Chu, Hou-De Zhang

    Background: Although reduced red blood cell (RBC) lifespan has been reported to be a contributory factor to anemia in patients with end-stage chronic kidney disease (CKD), there are limited data regarding RBC lifespan in early-stage CKD. Serum erythropoietin (EPO) is considered a primary causative factor of renal anemia. The aims of this study were to compare the RBC lifespan, serum EPO levels, and other renal anemia indicators across CKD-stage groups of patients and to analyze the impacts of etiological factors on renal anemia. Methods: A cohort of 74 non-smoking patients with CKD were enrolled, including 15 in stage 1, 18 in stage 2, 15 in stage 3, 15 in stage 4, and 11 in stage 5. RBC lifespan was determined by CO breath tests. Potential correlations of hemoglobin (Hb) concentration with RBC lifespan, reticulocyte count (Ret), and levels of EPO, ferritin, folic acid, and vitamin B12 were analyzed. Results: CKD progression was associated with decreases in (Hb) and RBC lifespan. RBC lifespan durations in CKD stages 1–5 were 122 ± 50, 112 ± 26, 90 ± 32, 88 ± 28, and 60 ± 24 days, respectively. RBC lifespan means for the stage 3, 4 and 5 groups were significantly shorter than those for the stage 1 and 2 groups. Serum EPO did not differ significantly between the CKD stage groups. (Hb) correlated directly with RBC lifespan (r = 0.372, p = 0.002) and Ret (r = 0.308, p = 0.011), but did not correlate with serum EPO, ferritin, folic acid, or vitamin B12 levels. Conclusions: Reduced RBC lifespan in early-stage CKD, demonstrated in this study, suggests that increased RBC destruction may play a more important etiological role in renal anemia than other indicators in patients with CKD.


  • Effect of Hemodialysis on the Red Blood Cell Life Span in Patients with End‐Stage Kidney Disease

    by Jun‐Feng Luo, Jiu‐Hong Li, Jun‐Jie Nie, Ping‐Ping Li, Hou‐De Zhang, Yong‐Jian Ma

    The aim of this study was to use a CO breath test to investigate hemodialysis effects on red blood cell lifespan in patients with chronic kidney disease. A cohort of 17 non‐smoking men with end‐stage kidney disease undergoing hemodialysis via a polysulfone dialysis membrane (as opposed to a traditional cellulose acetate membrane) were subjected to a repeated Levitt's CO breath test to compare red blood cell lifespan before vs. after dialysis. None of the patients showed significant fluctuations in endogenous CO concentration during the dialysis procedure. The mean red blood cell lifespan was 66.0 ± 31.0 days before dialysis and 72.0 ± 26.0 days after dialysis, with no significant difference between the assessment time points (P > 0.05). In conclusion, dialysis using a polysulfone membrane did not appear to disrupt red blood cells or reduce their lifespan in patients with end‐stage kidney disease.